Shares of Hims & Hers Health soared over 40% after drugmaker Novo Nordisk announced it will distribute its popular weight-loss drugs, including Wegovy and Ozempic, on the telehealth platform. This partnership resolves a prior dispute and allegations of patent infringement, marking a significant strategic shift for Hims & Hers, according to Yahoo Finance. The agreement grants Hims & Hers access to Novo Nordisk's full range of semaglutide-based treatments, ending a period of intense competition and legal conflict.
The deal not only boosts Hims & Hers' market position but also provides a clearer path for patient access to in-demand weight-loss medications. This new collaboration signals a potential shift in the competitive landscape of the rapidly expanding GLP-1 (glucagon-like peptide-1) agonist market.
What Does This Partnership Entail?
Under the new agreement, Hims & Hers will offer access to Novo Nordisk's injectable Ozempic and Wegovy, as well as the oral Wegovy pill, on its telehealth platform. This comprehensive offering includes all versions of Novo Nordisk's semaglutide-based weight-loss drugs, which have seen skyrocketing demand.In return, Hims & Hers has committed to discontinuing the advertisement of compounded GLP-1 drugs on its platform and in its marketing efforts. The company will now provide access to the branded medications at prices competitive with other telehealth providers, according to CNBC.
This development is a significant turnaround from the contentious relationship the two companies previously held. Hims & Hers’ stock closed up over 40% on the news, reflecting investor optimism about the expanded product offering and resolution of legal uncertainties.
Resolving a Contentious History
The new partnership concludes a long-standing feud between Hims & Hers and Novo Nordisk. Their business relationship first became tumultuous last year when a prior partnership dissolved in less than two months.
More recently, Novo Nordisk filed a lawsuit against Hims & Hers in February, alleging patent infringements related to semaglutide, the active ingredient in Ozempic and Wegovy. The lawsuit specifically targeted Hims & Hers for distributing what Novo Nordisk termed "mass illegal compounding" of its Wegovy pill. Hims had been offering a compounded version for approximately $49, significantly less than Novo Nordisk's branded pill priced around $100 via its direct-to-consumer platform, NovoCare, as reported by CNBC.
The resolution brings an end to these legal proceedings and allows both companies to focus on expanding access to FDA-approved weight-loss treatments. Michael Cherny, an analyst at Leerink Partners, described the rumored deal as "both a surprise and an unabashed positive for Hims’ stock."
